D.E. Shaw & Co
NDRM

D.E. Shaw & Co’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

D.E. Shaw & Co’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-67,391
Closed -$1.79M – 3726
2017
Q1 		$1.79M Buy
67,391
+40,215
+148% +$996K ﹤0.01% 1919
2016
Q4 		$603K Sell
27,176
-12,481
-31% -$233K ﹤0.01% 2744
2016
Q3 		$733K Sell
39,657
-6,819
-15% -$118K ﹤0.01% 2594
2016
Q2 		$755K Buy
46,476
+27,818
+149% +$469K ﹤0.01% 2580
2016
Q1 		$263K Buy
18,658
+4,006
+27% +$54.1K ﹤0.01% 3073
2015
Q4 		$250K Sell
14,652
-43,134
-75% -$840K ﹤0.01% 3466
2015
Q3 		$1.19M Buy
+57,786
New +$1.19M ﹤0.01% 2481

Other funds holding NDRM

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

D.E. Shaw & Co's NDRM Position: Q2 2017 in Review

D.E. Shaw & Co sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q2 2017, closing a stake of 67,391 shares — an estimated $1.79M sold.

D.E. Shaw & Co first reported a position in NDRM in Q3 2015 and held it in 7 quarters. The position peaked at $1.79M in Q1 2017. 73 funds tracked by Wall St. Rank hold NDRM as of Q2 2017.

  • D.E. Shaw & Co reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q2 2017 after selling out during the quarter.
  • D.E. Shaw & Co sold 67,391 NeuroDerm Ltd. Ordinary Shares shares in Q2 2017, an estimated $1.79M.
  • D.E. Shaw & Co first reported a position in NeuroDerm Ltd. Ordinary Shares in Q3 2015 and held it in 7 quarters.
  • D.E. Shaw & Co's NeuroDerm Ltd. Ordinary Shares position peaked at $1.79M in Q1 2017.
  • 73 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q2 2017.

Based on D.E. Shaw & Co's 13F filing for Q2 2017, filed 14 Aug 2017.